SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 65.61-0.5%Jun 14 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen10/25/2005 11:04:55 AM
   of 347
 
GenoMed CEO Honored for Innovation in Healthcare by St. Louis Business Journal

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com

ST. LOUIS--October 25, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its CEO, David W. Moskowitz MD, has been nominated as a finalist in the 2005 Health Care Heroes sponsored by the St. Louis Business Journal.


Now in its second year, the Health Care Heroes of St. Louis is an annual celebration organized by the St. Louis Business Journal to tell the stories of those who have benefited from the innovation and dedication of heroes in the health care profession. The event will be held November 10, 2005 in St. Louis (http://stlouis.bizjournals.com/stlouis/event/1916).

GenoMed currently earns revenues from its published protocols to reverse chronic kidney failure due to diabetes or high blood pressure, and delay progression of emphysema. These diseases affect 90 million Americans. The Company is currently conducting free trials for many additional diseases, including Parkinson's disease, Alzheimer's disease, most cancers, and viral diseases including West Nile virus encephalitis, regular influenza, and avian influenza.

Any one interested in signing up for GenoMed's trial just needs to go to GenoMed's website (www.genomed.com), and follow the links for the "Flu trial." The trial documents are self-explanatory.

About GenoMed

GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975).
.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext